Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
July 08, 2020 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
March 11, 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.
January 22, 2020 07:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
August 22, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug...
Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th
August 06, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
Seelos Therapeutics Reports Q2 2019 Pipeline Update
August 01, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
July 17, 2019 09:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...
Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
May 14, 2019 08:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed...
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
February 08, 2018 14:00 ET
|
Abeona Therapeutics Inc.
ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS...
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
February 07, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...